In summary, based on the data herein presented, we propose KCa3.1 as a possible marker of M/MΦ in the pro-tumor state, and thus a potential therapeutic target to induce GBM-associated M/MΦ to re-acquire a pro-inflammatory, antitumor activity. Here, KCNN4 is linked to glioblastoma.